Results -There was no difference in bronchodilator potency between fenoterol and salbutamol (as median dose ratio): FEV, 1 1 (95% CI 0 4 to 4.6). In contrast, dose ratios for systemic responses showed that fenoterol was more potent than salbutamol: serum potassium 3-7 (95% CI 2-0 to 6.0), tremor 5 7 (95% CI 1-4 to 10.2), heart rate 1-6 (95% CI 10 to 2.3). At a conventional dose of 200 ig the only difference in response between the two drugs was observed for tremor (as mean difference): 0-23 log units (95% CI 0-06 to 0-41 log units). Conclusions -There was no difference in the bronchodilator potency between fenoterol and salbutamol on a microgram equivalent basis. In contrast, systemic potency was greater with fenoterol, although this difference was not clinically relevant at conventional dosages up to 200 pg. (Thorax 1995;50:54-61) 
tivity of inhaled fenoterol and salbutamol in normal subjects. These initial findings have been extended by comparing the respective potencies of equivalent doses by weight offenoterol and salbutamol in asthmatic subjects, in terms of airways and systemic responses. Methods -Eighteen asthmatic patients of mean (SD) age 40 (14) years and a forced expiratory volume in one second (FEV,)% predicted of 56 (14)% (1.97 (0-66)1) were randomised to inhale fenoterol (100 tgIpuff or 200 igIpuff), salbutamol, or placebo (100 ig/puff or 200 pgIpuff) on three separate days. Dose-response curves were constructed using cumulative doses of 100 pg, 200 pg, 400 pg, 1000 tg, 2000 tg, and 4000 ptg, and airways and systemic responses were measured 20 minutes after each dose with 40 minute increments. Dose ratios for the relative potency of fenoterol versus salbutamol were calculated from the dose-response curves using regression analysis of parallel slopes. Results -There was no difference in bronchodilator potency between fenoterol and salbutamol (as median dose ratio): FEV, 1 1 (95% CI 0 4 to 4.6). In contrast, dose ratios for systemic responses showed that fenoterol was more potent than salbutamol: serum potassium [3] [4] [5] [6] [7] (95% CI 2-0 to 6.0), tremor 5 7 (95% CI 1-4 to 10.2), heart rate 1-6 (95% CI 10 to 2.3). At a conventional dose of 200 ig the only difference in response between the two drugs was observed for tremor (as mean difference): 0-23 log units (95% CI 0-06 to 0-41 log units). Conclusions -There was no difference in the bronchodilator potency between fenoterol and salbutamol on a microgram equivalent basis. In contrast, systemic potency was greater with fenoterol, although this difference was not clinically relevant at conventional dosages up to 200 pg. (Thorax 1995; 50:54-61) Keywords: potency, fenoterol, salbutamol, asthma, 02 adrenoceptor.
We have previously compared the relative cardiac 0 1 3 and 2 receptor activity of inhaled fenoterol and salbutamol in normal subjects and demonstrated no significant differences in the respective P11/12 receptor selectivity between the two drugs.' However, previous studies in asthmatic and normal subjects comparing equivalent doses (by weight) of inhaled fenoterol and salbutamol have shown fenoterol to produce a greater hypokalaemic response2 as well as greater chronotropic and electrocardiographic effects.34 The explanation for these differences is unclear, although it has been postulated that the greater liphophilicity of fenoterol might result in enhanced absorption across the lung vascular bed.5 An alternative explanation might be that fenoterol is a more potent stimulant of 12 adrenoceptors and will hence produce greater P2 mediated responses.6 However, previous studies in asthmatic patients have not addressed whether fenoterol and salbutamol produce different systemic effects when doses which produce equivalent bronchodilator responses are compared. 27 The aim of the present study was to evaluate the relative airways and systemic potencies of inhaled fenoterol and salbutamol at microgram equivalent doses in patients with stable asthma.
Methods

PATIENTS
Eighteen asthmatic patients gave written informed consent and were randomised, using a latin square design, into the double blind, placebo controlled crossover study which was approved by Tayside ethics committee. 
Systemic responses
All biochemical analyses were performed in batches at the end ofthe study and were assayed in duplicate. Serum levels of potassium were measured by flame photometry (IL943 analyser, Instrumentation Laboratory Ltd, Warrington, UK). The coefficients of variability for analytical imprecision within and between assays were 0i38% and 0A44%, respectively.
The normal reference range for our laboratory is 3 5-5 5 mmol/l. Salbutamol levels were measured by capillary gas chromatography using a 5160 Mega gas chromatograph (Carlo Erba, Milan, Italy) with a coupled mass spectrometer (Finnigan 4021, San Jose, California, USA). The coefficients of variation within and between assays were 5% and 20-30%, respectively. The limit of detection was 25 pg/ml. Fenoterol levels were measured by radioimmunoassay as described by Rominger et al. 9 The coefficient of variation within assays was 7 9% at 50 pg/ml and 5-6% at 500 pg/ml with a variation between assays of 5 5%. The limit of detection was 20 pg/ml.
The electrocardiogram was recorded on standard lead II using a monitor (Hewlett Packard, Palo Alto, California, USA) and printer with paper speed set at 50 mm/s and 0 5 mV/cm gain. The following parameters were measured from the mean of five consecutive complexes: R-R interval (s), Q-T interval (ms), T wave amplitude (mV), U wave frequency, and ST segment depression (mV). The Q-T interval was measured using the method described by Shamroth'0 to account for the presence of U waves. The formula of Bazett" was used to correct the Q-T interval for heart rate (Q-Tc).
The heart rate was calculated from the R-R interval. Systolic and diastolic blood pressures were recorded by a semi-automatic sphygmomanometer (Dinamap vital signs monitor, Critikon, USA). All measurments were taken from the right arm at one minute intervals until readings stabilised. The mean of three consistent readings was used in analysis. Stroke distance was measured non-invasively2 13 using a 1 9 MHz continuous wave non-imaging pencil probe (Hewlett Packard System 77020A). Recordings of ascending aortic blood flow were taken from the suprasternal notch and the mean ofthree consistent measurements ofthe systolic velocity integral (stroke distance) was used for the purpose of analysis. Stroke distance (cm) is the linear analogue of stroke volume (cm3), as the cross-sectional area of the aortic root is constant.
Finger tremor was recorded by a previously validated method'4 using an accelerometer transducer (Entran Ltd, Ealing, London, UK). Four recordings were taken and results were stored on computer disc for subsequent spectral analysis of tremor power (>2 Hz) by computerassisted autocovariance. The mean of three consistent readings was recorded and used for analysis.
STATISTICAL ANALYSIS Power
The primary end points were chosen before the study as potassium and FEVy. The sample size was chosen to be able to detect a treatment difference (fenoterol versus salbutamol) in serum potassium levels of 0 3 mmolIl, with 13 patients giving 80% power. The sample size was increased to 18 to make it possible to use a latin square design, balanced for treatment, period and crossover. More than 19 patients would have been required in order to detect a clinically relevant difference in FEV, (03 1).
Analysis
The treatment response was analysed as change from baseline, with tremor data being log transformed. Dose ratios were calculated from the dose-response curves using Theil's non-parametric regression, ' after the 4 mg dose were calculated for both drugs. All data analysis was performed using the Statistical Software package SAS (SAS Institute Inc, Cary, North Carolina, USA).
Results
There were no significant differences in baseline values between treatments for any of the parameters measured (table 2) .
PHARMACOKINETICS (fig 1)
Plasma fenoterol concentrations were lower than those of salbutamol but an approximately fourfold, dose-related increase occurred for both drugs. At the 1 mg dose the Cmax (ng/ ml) was 0 54 (95% CI 0 35 to 0 73) for fenoterol, and 2-54 (95% CI 1-33 to 3-74) for salbutamol. At the 4 mg dose values were 1-59 (95% CI 1-40 to 1-78) and 12-3 (95% CI 11-2 to 13-4) respectively. The AUC 0-120 (ng/ Values shown are medians and 95% CI for differences between fenoterol and salbutamol calculated from regression analysis of parallel slopes. The dose range for regression is also shown for each parameter. The dose ratios represent the amount of salbutamol required to produce the same effect as fenoterol (weight for weight). Those confidence intervals excluding unity suggest a difference in potency between the two drugs. Table 4 Responses for fenoterol versus salbutamol and salbutamol). In another study in mild asthmatic patients equivalent bronchodilator responses were also demonstrated with a ceiling being almost reached after two puffs using fenoterol 200 jig/puff and salbutamol 100 jig/ puff. Drug delivery to the lung vascular bed, and hence systemic absorption, will also be reduced by a decrease in airway calibre. The magnitude of systemic 12 effects would therefore be predicted to become attenuated in patients with more severe airflow obstruction. This hypothesis is supported by comparing peak plasma fenoterol levels at a dose of 4 mg in the present study in asthmatic subjects (1-59 ng/ml) with those in a previous study' in normal subjects (3i2 ng/ml). The twofold difference in levels is associated with an approximate 50% reduction in FEV1 between normal and asthmatic subjects. 
